Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: Preclinical and clinical studies

Clinical Cancer Research

Volumn 19, Issue 5, 2013, Pages 1244-1256

  Shin, Dong M ^a   Zhang, Hongzheng ^a   Saba, Nabil F ^a   Chen, Amy Y ^a   Nannapaneni, Sreenivas ^a   Amin, A R M Ruhul ^a   Müller, Susan ^a   Lewis, Melinda ^a   Sica, Gabriel ^a   Kono, Scott ^a   Brandes, Johann C ^a,d   Grist, William J ^a   Moreno Williams, Rachel ^a   Beitler, Jonathan J ^a   Thomas, Sufi M ^e   Chen, Zhengjia ^b   Shin, Hyung Ju C ^c   Grandis, Jennifer R ^e   Khuri, Fadlo R ^a   Chen, Zhuo Georgia ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^d ATLANTA VA MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELECOXIB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL LYSATE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG EFFICACY; ENZYME IMMUNOASSAY; ENZYME INHIBITION; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CYCLOOXYGENASE INHIBITORS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; PROGNOSIS; PYRAZOLES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 84874914651     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3149     Document Type: Article

References (55)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin 2012;62: 10-29.
2. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359: 1143-54.
3. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin Cancer Res 2006;12: 3661-97.
4. Fichtenberg CM, Glantz SA. Effect of smoke-free workplaces on smoking behaviour: systematic review. BMJ 2002;325: 188.
5. Bauer JE, Hyland A, Li Q, Steger C, Cummings KM. A longitudinal assessment of the impact of smoke-free worksite policies on tobacco use. Am J Public Health 2005;95: 1024-129.
6. Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin 2004;54: 150-80.
7. Lippman SM, Sudbo J, Hong WK. Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 2005;23: 346-56.
8. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333: 1157-60.
9. William WN Jr, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov 2009;8: 213-25.
10. Jain S, Khuri FR, Shin DM. Prevention of head and neck cancer: current status and future prospects. Curr Probl Cancer 2004;28: 265-86.
11. Day TA, Chi A, Neville B, Hebert Jr. Prevention of head and neck cancer. Curr Oncol Rep 2005;7: 145-53.
12. Lippman SM, Hong WK. Molecular markersof the risk of oral cancer. N. Engl J Med 2001;344: 1323-6.
13. Lippman SM. Cancer prevention research: back to the future. Cancer Prev Res (Phila) 2009;2: 503-513.
14. Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006;98: 441-50.
15. Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994;54: 3153-59.
16. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78: 1284-92.
17. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002;7 Suppl 4: 31-9.
18. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53: 3579-84.
19. Chai RL, Grandis Jr. Advances in molecular diagnostics and therapeutics in head and neck cancer. Curr Treat Options Oncol 2006;7: 3-11.
20. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19: 3267-79.
21. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000;1470:M69-78.
22. Saba NF, Choi M, Muller S, Shin HJ, Tighiouart M, Papadimitrakopoulou VA, et al. Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res 2009;2: 823-9.
23. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59: 991-994.
24. Hawk ET, Viner JL. Dannenberg A, DuBois RN, COX-2 in cancer-a player that's defining the rules. J Natl Cancer Inst 2002;94: 545-6.
25. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4: 431-6.
26. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase- 2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002;24: 792-9.
27. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342: 1946-52.
28. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94: 252-66.
29. Dogne JM, Hanson J, Supuran C, Pratico D. Coxibs and cardiovascular side-effects: from light to shadow. Curr Pharm Des 2006;12: 971-5.
30. Choe MS, Zhang X, Shin HJ, Shin DM, Chen ZG. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005;4: 1448-55.
31. Lippman SM, Gibson N, Subbaramaiah K, Dannenberg AJ. Combined targeting of the epidermal growth factor receptor and cyclooxygenase- 2 pathways. Clin Cancer Res 2005;11: 6097-9.
32. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005;23: 254-66.
33. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10: 5930-9.
34. Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005;11: 6261-9.
35. Saba NF, Muller S, Chen AY, Grist W, Gibson K, Nannapaneni S, et al. Chemoprevention with erlotinib and celecoxib in advanced premalignant lesions of the head and neck: Results of a phase I study. J Clin Oncol 2010;28: 15s (suppl; abstr 5535).
36. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82: 1107-12.
37. Zhang H, Su L, Muller S, Tighiouart M, Xu Z, Zhang X, et al. Restoration of caveolin-1 expression suppresses growth and metastasis of head and neck squamous cell carcinoma. Br J Cancer 2008;99: 1684-94.
38. Muller S, Su L, Tighiouart M, Saba N, Zhang H, Shin DM, et al. Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation. Cancer 2008;113: 97-107.
39. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143: 401-9.
40. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976;35: 1332-8.
41. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol 2010;7: 309-17.
42. Sawyers CL. The cancer biomarker problem. Nature 2008;452: 548-52.
43. Schmidt C. Larger companies dominate cancer companion diagnostic approvals. Nat Biotechnol 2011;29: 955-7.
44. Rozengurt E. Mitogenic signaling pathways induced by G proteincoupled receptors. J Cell Physiol 2007;213: 589-602.
45. Mitsiades CS, Mitsiades N, Koutsilieris M. The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets 2004;4: 235-56.
46. Kern SE. Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res 2012;72: 6097-6101.
47. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441: 424-30.
48. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18: 1926-1945.
49. Schneider A, Younis RH, Gutkind JS. Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia 2008;10: 1295-1302.
50. Raimondi AR, Molinolo A, Gutkind JS. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. Cancer Res 2009;69: 4159-66.
51. Khan Z, Khan N, Tiwari RP, Sah NK, Prasad GB, Bisen PS. Biology of Cox-2: an application in cancer therapeutics. Curr Drug Targets 2011;12: 1082-93.
52. Fu S, Rivera MKE, Sikora AG, Chen C-T, Vu HL, Cannan D, et al. Combined inhibition of epidermal growth factor receptor and cyclooxygenase- 2 as a novel approach to enhance radiotherapy. J Cell Sci Ther 2011;S1: 002.
53. Kao J, Genden EM, Chen CT, Rivera M, Tong CC, Misiukiewicz K, et al. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer 2011;117: 3173-81.
54. Wirth LJ, Haddad RI, Lindeman NI, Zhao X, Lee JC, Joshi VA, et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23: 6976-81.
55. Moskowitz HS, Gooding WE, Thomas SM, Freilino ML, Gross N, Argiris A, et al. Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer. Oral Oncol 2012;48: 1136-45.